Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

荃科得 - NMPA Drug Approval Details

Approvals/NMPA/Capivasertib Tablets

Approved

化学药品

Capivasertib Tablets

ASTRAZENECA UK LIMITED🇨🇳 National Medical Products Administration

Approval Date: Apr 15, 2025
Approval ID: 8jXhuV0KOSU
Company: ASTRAZENECA UK LIMITED
Type: 化学药品

Approval Details

Approval Id: 8jXhuV0KOSU
Approval Number: 国药准字HJ20250047
Generic Name: 卡匹色替片
Generic Name En: Capivasertib Tablets
Trade Name: 荃科得
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 200mg
Reg Date: 2025-04-15
Expired Date: 2030-04-14
Company Name: ASTRAZENECA UK LIMITED
Production Company Name: ASTRAZENECA AB
Company Detail Path: /organization/astrazeneca-uk-limited
Production Company Detail Path: /organization/astrazeneca-ab

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Apr 15, 2025

Approval ID

8jXhuV0KOSU

Type

化学药品

Back to NMPA Approvals